摘要
Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)is a dismal disease with a fast evolution and unpredictable treatment response.Nowadays,FOLFIRINOX[1]and gemcitabine[2]are the preferred treatments with a response rate of 33%and 11%,respectively.This poor patient response has been associated with an inefficient/non-personalized treatment allocation.Consequently,developing a rapid and efficient preclinical tool to test tumor drug sensitivity for each patient is hugely needed.Biopsy patient-derived organoid(PDO)appears to be a promising tool for developing individualized treatments for patients with PDAC.Several PDO-based platforms are in development worldwide as a guide to optimize therapy by directing tailored treatments.A critical point to consider PDO as promising is that it must represent the great clinical heterogeneity of PDAC as much as possible.Moreover,PDO has displayed histological features that mimic the PDAC phenotype.These characteristics make PDO an interesting option to obtaining reliable chemo-response profiles at a reasonable timeframe for most PDAC patients.
基金
The PaCaOmics study was registered at www.clinicaltrials.gov with registration number NCT01692873
PDAC samples were collected between January 2012 and December 2015.All experimental procedures on animals were approved by the Comitéd’éthique de Marseille numéro 14(C2EA-14).
